Who
Christine Mikail Cvijic
President and CFO
Company insider
Files Form 4 as: President and CFO, Neurogene; Chief Admin Officer and GC, Axovant Sciences; SVP, Legal Affairs & GC, Nps Pharmaceuticals; EVP, Corp Dev, Gen Cnsl/Scrtry, Dendreon.
In numbers
- Trades disclosed
- 52
- Buys
- 1
- Sells
- 9
- Bought
- $492K
- Sold
- $1.9M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 8 Mar 2012
- Last trade
- 7 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 7 Jul 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $152K4,200 at $36.13 | filing |
| 7 Jul 2026filed 7 Jul 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $152K4,200 at $36.13 | filing |
| 6 Jul 2026filed 7 Jul 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $22K600 at $36.02 | filing |
| 6 Jul 2026filed 7 Jul 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $22K600 at $36.02 | filing |
| 2 Jul 2026filed 2 Jul 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $88K2,531 at $34.58 | filing |
| 2 Jul 2026filed 2 Jul 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $54K1,530 at $35.23 | filing |
| 2 Jul 2026filed 2 Jul 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $88K2,531 at $34.58 | filing |
| 2 Jul 2026filed 2 Jul 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $54K1,530 at $35.23 | filing |
| 1 Jul 2026filed 2 Jul 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $25K739 at $34.06 | filing |
| 1 Jul 2026filed 2 Jul 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $25K739 at $34.06 | filing |
| 6 May 2026filed 8 May 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $144K4,800 at $30.07 | filing |
| 6 May 2026filed 8 May 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $156K4,800 at $32.44 | filing |
| 6 May 2026filed 8 May 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $144K4,800 at $30.07 | filing |
| 6 May 2026filed 8 May 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $156K4,800 at $32.44 | filing |
| 26 Mar 2026filed 30 Mar 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $55K2,558 at $21.62 | filing |
| 26 Mar 2026filed 30 Mar 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $55K2,558 at $21.62 | filing |
| 13 Mar 2026filed 17 Mar 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $49K2,387 at $20.42 | filing |
| 13 Mar 2026filed 17 Mar 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $30K1,395 at $21.25 | filing |
| 13 Mar 2026filed 17 Mar 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $5,791263 at $22.02 | filing |
| 13 Mar 2026filed 17 Mar 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $49K2,387 at $20.42 | filing |
News
Critical Contrast: Intellia Therapeutics (NASDAQ:NTLA) vs. Neurogene (NASDAQ:NGNE)NGNE · themarketsdaily.com · 24 Oct 2026Neurogene Inc.: Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual CongressNGNE · finanznachrichten.de · 20 Oct 2026
0 headlines in the last 90 days name Christine Mikail Cvijic; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.